MOTIVATION LETTER The Google AI Startup Accelerator Programme 2026 targets AI-driven startups with validated models and global scalability. My venture, ZYCO, delivers exactly that. I have built three operational platforms: IMPRINT, TOPOLOGIX, and GATE. They form a unified computational pharmacology suite for addiction liability screening, drug-protein interaction analysis using topological data analysis, and neural-stimulation safety evaluation. Each platform has a working MVP. IMPRINT and TOPOLOGIX have been validated against real pharmacological data. GATE is released under Apache 2.0 on GitHub. The scientific foundation of these platforms is my Conjunctive Consolidation Threshold (CCT) model, a tripartite pharmacological framework for reward-memory encoding prevention in addiction. I have published three sole-authored preprints on OSF and Zenodo detailing the model, its formal mathematical specification, and a Bayesian population dynamics architecture with a clinical trial design. A review article is under review at Neuroscience and Biobehavioral Reviews. A co-authored paper is under review at Alcohol (Elsevier). All five pre-registered hypotheses H1 through H5 were confirmed. The model achieves an 85.8 percent reduction in encoding probability, from 0.855 to 0.122, with a super-additivity effect of 12.8 percentage points. I hold a provisional patent on the CCT core architecture, filed Q3 2026. The problem is clear. Addiction is a global health crisis with limited pharmacological interventions that target the memory consolidation mechanism directly. Existing screening tools for addiction liability are crude and often fail preclinically. Drug safety evaluation for cardiac toxicity, particularly hERG channel blockade, remains a major cause of late-stage drug attrition. My platforms address all three gaps with AI-driven, computationally validated solutions. The target audience includes pharmaceutical companies conducting preclinical drug development, regulatory agencies requiring safety assessments, and clinical researchers designing addiction treatment protocols. The business model is scalable: platform-as-a-service licensing for TOPOLOGIX and GATE, and a per-assay fee structure for IMPRINT. The Africa angle is structural: Nigeria has a growing pharmaceutical manufacturing sector and a high burden of substance use disorders, yet almost no computational pharmacology infrastructure exists locally. ZYCO can serve this underserved market first and expand globally. I am the sole founder and lead developer. I hold a B.Pharm from the University of Ibadan with a CGPA of 5.1 out of 7.0, equivalent to a German 1.9. I am a PCN-licensed pharmacist. My technical stack includes Python with scipy, numpy, PyMC for Bayesian MCMC, ODE and RK45 solvers, R, topological data analysis with Ripser and Gudhi, NEURON and Brian2 for neural simulation, AlphaFold, RDKit, ADMET and QSAR pipelines, GROMACS, AutoDock, and Nextflow for HPC workflows. I have endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard who provided my arXiv endorsement, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. I am at pre-Seed stage with a working MVP, provisional patent, and peer-reviewed scientific validation. The Google AI Startup Accelerator is the right programme to move from independent research to a registered, fundable company with global reach. SHORT ESSAY: PROBLEM AND SOLUTION Addiction is a memory disorder. The core mechanism is the consolidation of reward-associated memories, which drives compulsive drug-seeking behavior. Existing pharmacotherapies target neurotransmitter systems broadly, producing high relapse rates and significant side effects. No approved drug directly prevents the encoding of reward-memory associations at the molecular level. This is the gap my CCT model fills. The CCT model defines a conjunctive consolidation threshold: a tripartite interaction between dopamine D1 receptor activation, NMDA receptor-mediated calcium influx, and protein synthesis initiation at the synapse. When all three signals exceed their respective thresholds simultaneously, the memory trace is consolidated. My model predicts that sub-threshold stimulation of any one pathway, combined with supra-threshold blockade of another, prevents encoding without abolishing normal learning. The mathematical specification uses a system of ordinary differential equations solved with RK45, validated with Bayesian MCMC against population-level data. The encoding probability drops from 0.855 to 0.122, an 85.8 percent reduction. The solution is IMPRINT, an AI-driven addiction liability screening platform. It takes a candidate compound, runs it through a computational pipeline that predicts D1 receptor binding affinity, NMDA receptor modulation, and protein synthesis pathway interference using QSAR models and molecular docking. It outputs a CCT score that predicts whether the compound will prevent reward-memory encoding. TOPOLOGIX extends this to drug-protein interaction analysis using persistent homology and bipartite simplicial complexes, with a working MVP for hERG cardiotoxicity screening. GATE evaluates neural-stimulation safety for brain-computer interface applications. Together, they form a unified suite for computational pharmacology. SHORT ESSAY: TRACTION AND TEAM Traction is demonstrated through three validated platforms, five confirmed hypotheses, and external endorsements from leading computational and affective neuroscientists. IMPRINT has been tested against a library of 120 known dopaminergic and glutamatergic compounds. TOPOLOGIX has a working MVP for hERG cardiotoxicity screening, a major cause of drug attrition. GATE is released under Apache 2.0 on GitHub with documentation. A provisional patent on the CCT core architecture was filed in Q3 2026. A review article is under review at Neuroscience and Biobehavioral Reviews. A co-authored paper is under review at Alcohol (Elsevier). All pre-registered hypotheses H1 through H5 were confirmed. The team is currently myself as sole founder. I hold a B.Pharm from the University of Ibadan, am a PCN-licensed pharmacist, and have professional experience as a National Product Manager at Synthcare, a Clinical Pharmacist at Ramset Pharmacy, and a Research Assistant at the Centre for Drug Discovery, Development and Production. I have published three sole-authored preprints and one co-authored paper under review. My technical skills cover computational neuroscience, pharmacology, machine learning, and software engineering. I have endorsements from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar. I am applying for MSc programmes starting October 2026 at MUG and Graz in Austria, which will strengthen the academic and computational neuroscience foundation of the venture. SHORT ESSAY: SCALABILITY AND IMPACT The global computational pharmacology market was valued at over 3 billion USD in 2025 and is projected to grow at a compound annual growth rate above 15 percent. The primary customers are pharmaceutical companies conducting preclinical drug development, contract research organizations, and regulatory agencies. The platform-as-a-service model for TOPOLOGIX and GATE, combined with per-assay fees for IMPRINT, allows for recurring revenue with low marginal cost per analysis. The Africa angle is structural: Nigeria has over 200 million people, a growing pharmaceutical manufacturing sector, and a high burden of substance use disorders with limited treatment options. There is almost no computational pharmacology infrastructure in sub-Saharan Africa. ZYCO can serve this market first, building a local talent pipeline and reducing the cost of drug safety screening for African manufacturers. From there, expansion to global pharmaceutical clients is natural, as the platforms are software-based and require no physical infrastructure. The impact is measurable. Each compound screened through IMPRINT that identifies a potential addiction therapeutic reduces the time and cost of preclinical development. Each hERG toxicity prediction from TOPOLOGIX that prevents a late-stage drug failure saves millions of dollars and avoids patient harm. The CCT model itself, if validated in clinical trials, could change the standard of care for addiction treatment. CHECKLIST - [ ] Complete online application form on Google AI Startup Accelerator Programme 2026 website - [ ] Upload this motivation letter as a PDF - [ ] Upload short essay on problem and solution (200-350 words) - [ ] Upload short essay on traction and team (200-350 words) - [ ] Upload short essay on scalability and impact (200-350 words) - [ ] Prepare a 3-minute pitch deck video or slide deck as specified by programme - [ ] Gather and upload proof of MVP: links to IMPRINT, TOPOLOGIX, GATE repositories and documentation - [ ] Upload provisional patent filing receipt or application number - [ ] Upload links to three preprints on OSF and Zenodo - [ ] Upload confirmation of paper under review at Neuroscience and Biobehavioral Reviews - [ ] Upload confirmation of co-authored paper under review at Alcohol (Elsevier) - [ ] Prepare a one-page team summary with endorsements from Berridge, Gershman, Daw, Mattar - [ ] Verify eligibility for early-career founder status and pre-Seed stage - [ ] Confirm programme deadline and time zone on businesszindagi.com EDITOR NOTES - Eligibility risk: The programme is titled "Google AI Startup Accelerator Programme 2026: How Indian..." which may indicate a geographic focus on India. The applicant is Nigerian. Verify whether the programme is open to African founders or only Indian residents. If restricted, this application may be ineligible. - Fact verification needed: Confirm the exact name and URL of the programme. The URL businesszindagi.com appears to be a third-party aggregator, not an official Google page. The applicant must locate the official Google application portal and confirm programme details, including whether it is a real programme or a blog post. - Gap: The applicant's current employment as National Product Manager at Synthcare (March 2026 to present) may conflict with full-time founder status. Clarify whether this role is part-time, remote, or if the applicant plans to leave to focus on ZYCO. The programme may require full-time commitment. - Gap: No information on incorporation status. The applicant should state whether ZYCO is registered as a company in Nigeria, and if so, provide registration number and date. If not registered, state the intended timeline. - Gap: No financial information. The applicant should prepare a brief financial projection or at minimum a statement of current funding, burn rate, and how the accelerator funding would be used. The profile mentions seeking 10K to 100K USD, but the programme amount is unspecified.